Furthermore, stratification of patients with severe asthma based on blood eosinophil counts may predict clinical responsiveness to anti-eosinophil therapies, such as mepolizumab and reslizumab (anti-interleukin [IL]-5 antibodies) and benralizumab (anti-IL-5 receptor α antibody) [8–10]. The gene discussed is IL5; the disease is asthma.